Agreement Reached to Test Hu5F9-G4 and Avelumab Combo for Ovarian Cancer

Agreement Reached to Test Hu5F9-G4 and Avelumab Combo for Ovarian Cancer
A new Phase 1b clinical trial testing a combination treatment of Hu5F9-G4 with avelumab in patients with ovarian cancer is set to begin as part of an agreement between Forty Seven and Merck KGaA, Darmstadt, Germany. “Ovarian cancer patients have limited treatment options, especially as they are often diagnosed at a late stage in their disease,” Alise Reicin, head of

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *